Riskpilot← Back to searchSign inGet full accessAstermark Medical Consulting AB
ABActiveOrg 5568066608Strandpromenaden 14Business and other management consultancy activities · NACE 7020Est. 20100 employees
Revenue 2025
SEK 740K
-8% vs 2024
EBITDA margin
82.3%
0% vs 2024
Equity ratio
73.2%
Financial strength
Net profit 2025
SEK 553K
+26% vs 2024
| Revenue | SEK 740K | -8% |
| EBITDA | SEK 609K | +0% |
| Net profit | SEK 553K | +26% |
| Total assets | SEK 4,3M | +14% |
| Equity | SEK 3,1M | +15% |
| Employees | 0 | — |
Legal name
Astermark Medical Consulting AB
Org number
5568066608
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
26 april 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva internationell internmedicinsk konsultverksamhet vilken skall vara baserad på kliniska erfarenheter, vetenskapliga sammanställningar samt nya forskningsrön. Konsultverksamheten innefattar föredrag, utbildning, medverkan i expertråd och vetenskapliga paneler, utarbetande av behandlingsråd samt därmed förenlig verksamhet.
Address
Strandpromenaden 14
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 403 | 553 | 558 | 802 | 740 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 355 | 468 | 469 | 607 | 609 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 355 | 468 | 469 | 607 | 609 |
| Net financials | 36 | 18 | 19 | 35 | 179 |
| Profit before tax | 334 | 383 | 413 | 562 | 708 |
| Tax | −79 | −80 | −91 | −124 | −155 |
| Net profit | 255 | 303 | 322 | 438 | 553 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 217 | 3 600 | 3 927 | 3 732 | 4 251 |
| Equity | 2 525 | 2 798 | 3 020 | 2 708 | 3 111 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 42 | 49 | 79 | 116 | 153 |
| Total debt | 42 | 49 | 79 | 116 | 153 |
EBITDA margin
82.3%
This company
15.8%
Market median
+421% vs market
20212025
Equity ratio
73.2%
This company
38.2%
Market median
+92% vs market
20212025
Return on equity
17.8%
This company
18.4%
Market median
+3% vs market
20212025
Net profit margin
74.7%
This company
8.1%
Market median
+822% vs market
20212025
Asset turnover
0.17×
This company
1.12×
Market median
-85% vs market
20212025
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Astermark Medical Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stig Jan Peter Astermark | Board of Directors | 0 companies |
| Alexander Jan Markus Astermark | Deputy Board Member | 0 companies |
| Stig Gösta Ingemar Astermark | Deputy Board Member | 0 companies |